ALK陽性非小細胞肺癌患者におけるLDK378（アレクチニブによる治療歴あり）。

基本情報

NCT ID

NCT02450903

ステータス

完了

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

20

治験依頼者名

Novartis

概要

This was a single-arm, open-label, multicenter, phase II study to evaluate the efficacy and safety of the ALK inhibitor LDK378 when used as single agent in patients with ALK-rearranged stage IIIB or IV NSCLC previously treated with alectinib. Treatment with LDK378 750 mg qd continued until the patient experienced disease progression as determined by the investigator according to RECIST 1.1, unacceptable toxicity that precluded further treatment, pregnancy, start of a new anticancer therapy, discontinued treatment at the discretion of the patient or investigator, lost to follow-up, death, or study was terminated by Sponsor.

対象疾患

介入

依頼者（Sponsor）